Certified by Founder
Lodge
Adcendo
start up
Denmark
- Copenhagen, Capital Region of Denmark
- 26/11/2024
- Series B
- $135,000,000
Adcendo seeks to develop antibody-drug conjugates to create new medicines for cancer patients with a significant unmet need.
The company was founded in 2017 in Copenhagen, as a spin-out from The Finsen Laboratory of Rigshospitalet and the University of Copenhagen.
- Industry Biotechnology Research
- Website https://adcendo.com/
- LinkedIn https://www.linkedin.com/company/adcendo/
Humand | $66,000,000 | (Feb 24, 2026)
Solid (AI for Data) | $20,000,000 | (Feb 24, 2026)
Comeryx | $7,500,000 | (Feb 24, 2026)
Maazah | $2,000,000 | (Feb 24, 2026)
Turgo.ai | $1,000,000 | (Feb 24, 2026)
Sherpas | $3,200,000 | (Feb 24, 2026)
Patientdesk.ai (YC W26) | $1,000,000 | (Feb 24, 2026)
Aalyria | $100,000,000 | (Feb 24, 2026)
Ubicquia, Inc | $106,000,000 | (Feb 24, 2026)
Freeform | $67,000,000 | (Feb 24, 2026)
Coral Care | $13,000,000 | (Feb 24, 2026)
Reload | $2,275,000 | (Feb 24, 2026)